Web tracking technologies in the following categories are used on our website. You may opt out of certain trackers as described below.

Necessary

These trackers are necessary for the website to function properly. They are usually set in response to actions made by you which amount to a request for services. You can set your browser to block or alert you about these trackers, but some parts of the site may no longer function.

Advertising

These trackers allow us to optimize advertising. They may be set on our site through advertising providers, which may use those trackers to build a profile of your interests and show you relevant ads on other sites and social media. You may opt out of these trackers.

Performance

These trackers allow us to monitor site visits and traffic sources so that we can measure, analyze, and improve the performance of our site. You may opt out of these trackers.

Confirm choices

Mental Health:
the capacity to work, play and love

Work: to make meaningful impact
Play: to be active for joy and pleasure
Love: to express affection without anxiety

Starting with guided Ketamine therapy for anxiety and depression, the Mindbloom program is designed to help you achieve the relief you need, to build the life you want.

Am I a Candidate?
Safety information
Important Safety Information

Mindbloom pairs individuals with licensed clinicians who are trained to diagnose and treat anxiety, depression, and other mental health conditions.  If one of the licensed clinicians, in their medical judgment, decides that ketamine is an appropriate treatment for an individual based on a clinical assessment, then the clinician may prescribe ketamine tablets that are compounded by pharmacies under Section 503A of the federal Food, Drug, and Cosmetic Act (FDCA).  Drugs compounded under Section 503A do not require FDA approval, and as such the FDA has not determined that the compounded ketamine prescribed is safe and effective for anxiety, depression, or other mental health conditions.  The use of ketamine for anxiety, depression, and many other mental health conditions, however, is supported by a body of scientific literature.  (Data on file).

Ketamine is a Schedule III controlled substance. Other drugs containing ketamine, which (unlike compounded drugs) are subject to FDA’s approval requirements, have been FDA-approved as an intravenous or intramuscular injection solution for induction and maintenance of general anesthesia. However, those drugs have not been FDA-approved for anxiety, depression, or other mental health conditions, and they have not been FDA-approved in tablet form. The approved label is available here.

Ketamine may cause serious side effects, including but not limited to risks of: sedation; dissociation; psychiatric events or worsening of psychiatric disorders, including problems in people with schizophrenia, severe personality disorders, or other serious mental disorders; dependence, abuse and misuse; anxiety; increases in blood pressure or heart rate; respiratory depression (breathing becomes slower and shallower and the lungs fail to exchange carbon dioxide and oxygen efficiently); lower urinary tract and bladder symptoms, including frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size; altered sense of time; dry mouth; elevated intraocular or intracranial pressure; loss of appetite; confusion; nausea/vomiting; blurred vision; and slurred speech.

The FDA has advised that at-home administration of compounded ketamine may present additional risks because a health care provider is not available onsite to monitor for adverse outcomes resulting from sedation and dissociation.

Mindbloom’s protocols and guidance have been designed to minimize the likelihood of experiencing these side effects or other adverse effects, and should be followed carefully. Ketamine should only be taken as directed by the treating clinician.

Do not proceed with ketamine treatment if any of the following apply to you:

  • Allergic to ketamine
  • Symptoms of psychosis or mania
  • Uncontrolled high blood pressure
  • CHF or other serious heart problem
  • Severe breathing problem
  • History of elevated intraocular or intracranial pressure
  • History of hyperthyroidism
  • Other serious medical illness
  • Pregnant, nursing, or trying to become pregnant

Ketamine has been found to cause moderate psychological dependency in some users.

  • In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
  • Ketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders
  • Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including ketamine, and discuss potential risks with your clinician before proceeding with treatment
  • The dissociative effects of ketamine may increase patient vulnerability and the risk of accidents

To promote positive outcomes and ensure safety, follow these ketamine treatment guidelines:

  • Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep
  • Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
  • Continue to take antihypertensive medication as prescribed
  • Do not take ketamine while hungover or with alcoholic beverages
  • Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
  • Ketamine treatment should never be conducted without a peer treatment monitor physically present

A peer-reviewed study of Mindbloom’s client treatment outcomes was published in the Journal of Affective Disorders in 2022, titled At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. The FDA has not evaluated head-to-head trials comparing the safety of ketamine to other medications that are FDA-approved for the treatment of depression, anxiety, or other psychiatric disorders. Although some clients report that they had more success with ketamine than with FDA-approved therapies, these outcomes may not be typical.

For more information about the informed consent that clients review and sign prior to treatment, please visit mindbloom.com/informed-consent.

In the News

Heathline
The New York Times
Forbes
Womens Health
Newsweek

It’s not you, it’s your brain

When people suffer from long-lasting social and emotional stress, their neurons become stunted with fewer connections. It becomes harder for the brain to carry out executive function —the ability to control short-term behaviors in favor of self control, planning, decision making, problem solving, and long-term goals.

Over time, this creates an insidious paradox; the neurobiology of the “depressed” or “anxious” brain inhibits the affected individual from enacting lifestyle changes that will enable them to achieve meaning and fulfillment in different areas of their life.

That’s where ketamine comes in.

Safety Information
Take assessment
Pills
Safety information
Important Safety Information

Mindbloom pairs individuals with licensed clinicians who are trained to diagnose and treat anxiety, depression, and other mental health conditions.  If one of the licensed clinicians, in their medical judgment, decides that ketamine is an appropriate treatment for an individual based on a clinical assessment, then the clinician may prescribe ketamine tablets that are compounded by pharmacies under Section 503A of the federal Food, Drug, and Cosmetic Act (FDCA).  Drugs compounded under Section 503A do not require FDA approval, and as such the FDA has not determined that the compounded ketamine prescribed is safe and effective for anxiety, depression, or other mental health conditions.  The use of ketamine for anxiety, depression, and many other mental health conditions, however, is supported by a body of scientific literature.  (Data on file).

Ketamine is a Schedule III controlled substance. Other drugs containing ketamine, which (unlike compounded drugs) are subject to FDA’s approval requirements, have been FDA-approved as an intravenous or intramuscular injection solution for induction and maintenance of general anesthesia. However, those drugs have not been FDA-approved for anxiety, depression, or other mental health conditions, and they have not been FDA-approved in tablet form. The approved label is available here.

Ketamine may cause serious side effects, including but not limited to risks of: sedation; dissociation; psychiatric events or worsening of psychiatric disorders, including problems in people with schizophrenia, severe personality disorders, or other serious mental disorders; dependence, abuse and misuse; anxiety; increases in blood pressure or heart rate; respiratory depression (breathing becomes slower and shallower and the lungs fail to exchange carbon dioxide and oxygen efficiently); lower urinary tract and bladder symptoms, including frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size; altered sense of time; dry mouth; elevated intraocular or intracranial pressure; loss of appetite; confusion; nausea/vomiting; blurred vision; and slurred speech.

The FDA has advised that at-home administration of compounded ketamine may present additional risks because a health care provider is not available onsite to monitor for adverse outcomes resulting from sedation and dissociation.

Mindbloom’s protocols and guidance have been designed to minimize the likelihood of experiencing these side effects or other adverse effects, and should be followed carefully. Ketamine should only be taken as directed by the treating clinician.

Do not proceed with ketamine treatment if any of the following apply to you:

  • Allergic to ketamine
  • Symptoms of psychosis or mania
  • Uncontrolled high blood pressure
  • CHF or other serious heart problem
  • Severe breathing problem
  • History of elevated intraocular or intracranial pressure
  • History of hyperthyroidism
  • Other serious medical illness
  • Pregnant, nursing, or trying to become pregnant

Ketamine has been found to cause moderate psychological dependency in some users.

  • In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
  • Ketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders
  • Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including ketamine, and discuss potential risks with your clinician before proceeding with treatment
  • The dissociative effects of ketamine may increase patient vulnerability and the risk of accidents

To promote positive outcomes and ensure safety, follow these ketamine treatment guidelines:

  • Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep
  • Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
  • Continue to take antihypertensive medication as prescribed
  • Do not take ketamine while hungover or with alcoholic beverages
  • Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
  • Ketamine treatment should never be conducted without a peer treatment monitor physically present

A peer-reviewed study of Mindbloom’s client treatment outcomes was published in the Journal of Affective Disorders in 2022, titled At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. The FDA has not evaluated head-to-head trials comparing the safety of ketamine to other medications that are FDA-approved for the treatment of depression, anxiety, or other psychiatric disorders. Although some clients report that they had more success with ketamine than with FDA-approved therapies, these outcomes may not be typical.

For more information about the informed consent that clients review and sign prior to treatment, please visit mindbloom.com/informed-consent.

The Neuroscience

The next chapter in mental health and well-being

Ketamine therapy is uniquely poised to be effective in the treatment of anxiety and depression due to how it can fuel neural growth and promote novel perspectives and insights — new ways of thinking and approaching aspects of life.

Am I a Candidate?

Heal your brain

Heal damaged neurons and forge new connections

By helping the brain produce a special protein called “brain-derived neurotrophic factor” (BDNF), ketamine has been shown to fertilize neural growth, and help deconstruct old patterns and behaviors by enhancing neuroplasticity — the brain’s ability to adapt and respond appropriately to its own activity

Change your mind

Uncover fresh insights and form new perspectives

Each session is an access point to the blind spots of the logical, conscious mind. When integrated, these insights can provide powerful and significant changes to how the individual views themselves and the world around them.

Transform your life

Unlock the path to reach your full potential

Ketamine isn’t a “daily pill”, it’s a catalyst for personal transformation. The biological and psychological benefits of each dosing session are meant to open an individual up to thought patterns and behaviors that are holding them back from reaching their full potential.

The Outcomes

Powerful Results

Mindbloom’s ketamine therapy helps to transform lives. In a clinical study of outcomes:

89%

of Mindbloom clients reported improvement in their depression and anxiety symptoms after 4 sessions

Safety information
Important Safety Information

Mindbloom pairs individuals with licensed clinicians who are trained to diagnose and treat anxiety, depression, and other mental health conditions.  If one of the licensed clinicians, in their medical judgment, decides that ketamine is an appropriate treatment for an individual based on a clinical assessment, then the clinician may prescribe ketamine tablets that are compounded by pharmacies under Section 503A of the federal Food, Drug, and Cosmetic Act (FDCA).  Drugs compounded under Section 503A do not require FDA approval, and as such the FDA has not determined that the compounded ketamine prescribed is safe and effective for anxiety, depression, or other mental health conditions.  The use of ketamine for anxiety, depression, and many other mental health conditions, however, is supported by a body of scientific literature.  (Data on file).

Ketamine is a Schedule III controlled substance. Other drugs containing ketamine, which (unlike compounded drugs) are subject to FDA’s approval requirements, have been FDA-approved as an intravenous or intramuscular injection solution for induction and maintenance of general anesthesia. However, those drugs have not been FDA-approved for anxiety, depression, or other mental health conditions, and they have not been FDA-approved in tablet form. The approved label is available here.

Ketamine may cause serious side effects, including but not limited to risks of: sedation; dissociation; psychiatric events or worsening of psychiatric disorders, including problems in people with schizophrenia, severe personality disorders, or other serious mental disorders; dependence, abuse and misuse; anxiety; increases in blood pressure or heart rate; respiratory depression (breathing becomes slower and shallower and the lungs fail to exchange carbon dioxide and oxygen efficiently); lower urinary tract and bladder symptoms, including frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size; altered sense of time; dry mouth; elevated intraocular or intracranial pressure; loss of appetite; confusion; nausea/vomiting; blurred vision; and slurred speech.

The FDA has advised that at-home administration of compounded ketamine may present additional risks because a health care provider is not available onsite to monitor for adverse outcomes resulting from sedation and dissociation.

Mindbloom’s protocols and guidance have been designed to minimize the likelihood of experiencing these side effects or other adverse effects, and should be followed carefully. Ketamine should only be taken as directed by the treating clinician.

Do not proceed with ketamine treatment if any of the following apply to you:

  • Allergic to ketamine
  • Symptoms of psychosis or mania
  • Uncontrolled high blood pressure
  • CHF or other serious heart problem
  • Severe breathing problem
  • History of elevated intraocular or intracranial pressure
  • History of hyperthyroidism
  • Other serious medical illness
  • Pregnant, nursing, or trying to become pregnant

Ketamine has been found to cause moderate psychological dependency in some users.

  • In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
  • Ketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders
  • Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including ketamine, and discuss potential risks with your clinician before proceeding with treatment
  • The dissociative effects of ketamine may increase patient vulnerability and the risk of accidents

To promote positive outcomes and ensure safety, follow these ketamine treatment guidelines:

  • Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep
  • Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
  • Continue to take antihypertensive medication as prescribed
  • Do not take ketamine while hungover or with alcoholic beverages
  • Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
  • Ketamine treatment should never be conducted without a peer treatment monitor physically present

A peer-reviewed study of Mindbloom’s client treatment outcomes was published in the Journal of Affective Disorders in 2022, titled At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. The FDA has not evaluated head-to-head trials comparing the safety of ketamine to other medications that are FDA-approved for the treatment of depression, anxiety, or other psychiatric disorders. Although some clients report that they had more success with ketamine than with FDA-approved therapies, these outcomes may not be typical.

For more information about the informed consent that clients review and sign prior to treatment, please visit mindbloom.com/informed-consent.

Clinical Study Key Findings

Relief From Symptoms

89%

of Mindbloom clients reported improvement in their depression and anxiety symptoms after 4 sessions

Relief From Suicidal Thoughts

62%

of participants who reported suicidal ideation no longer reported any suicidal ideation after 4 sessions

Little to No Side Effects

95%

of clients reported no side effects from their ketamine treatment with Mindbloom.

Symptom Remission is Possible

30%

of clients experiencing depression and anxiety achieved remission (or virtually no symptoms) after 4 sessions.

Safety information
Important Safety Information

Mindbloom pairs individuals with licensed clinicians who are trained to diagnose and treat anxiety, depression, and other mental health conditions.  If one of the licensed clinicians, in their medical judgment, decides that ketamine is an appropriate treatment for an individual based on a clinical assessment, then the clinician may prescribe ketamine tablets that are compounded by pharmacies under Section 503A of the federal Food, Drug, and Cosmetic Act (FDCA).  Drugs compounded under Section 503A do not require FDA approval, and as such the FDA has not determined that the compounded ketamine prescribed is safe and effective for anxiety, depression, or other mental health conditions.  The use of ketamine for anxiety, depression, and many other mental health conditions, however, is supported by a body of scientific literature.  (Data on file).

Ketamine is a Schedule III controlled substance. Other drugs containing ketamine, which (unlike compounded drugs) are subject to FDA’s approval requirements, have been FDA-approved as an intravenous or intramuscular injection solution for induction and maintenance of general anesthesia. However, those drugs have not been FDA-approved for anxiety, depression, or other mental health conditions, and they have not been FDA-approved in tablet form. The approved label is available here.

Ketamine may cause serious side effects, including but not limited to risks of: sedation; dissociation; psychiatric events or worsening of psychiatric disorders, including problems in people with schizophrenia, severe personality disorders, or other serious mental disorders; dependence, abuse and misuse; anxiety; increases in blood pressure or heart rate; respiratory depression (breathing becomes slower and shallower and the lungs fail to exchange carbon dioxide and oxygen efficiently); lower urinary tract and bladder symptoms, including frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size; altered sense of time; dry mouth; elevated intraocular or intracranial pressure; loss of appetite; confusion; nausea/vomiting; blurred vision; and slurred speech.

The FDA has advised that at-home administration of compounded ketamine may present additional risks because a health care provider is not available onsite to monitor for adverse outcomes resulting from sedation and dissociation.

Mindbloom’s protocols and guidance have been designed to minimize the likelihood of experiencing these side effects or other adverse effects, and should be followed carefully. Ketamine should only be taken as directed by the treating clinician.

Do not proceed with ketamine treatment if any of the following apply to you:

  • Allergic to ketamine
  • Symptoms of psychosis or mania
  • Uncontrolled high blood pressure
  • CHF or other serious heart problem
  • Severe breathing problem
  • History of elevated intraocular or intracranial pressure
  • History of hyperthyroidism
  • Other serious medical illness
  • Pregnant, nursing, or trying to become pregnant

Ketamine has been found to cause moderate psychological dependency in some users.

  • In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
  • Ketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders
  • Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including ketamine, and discuss potential risks with your clinician before proceeding with treatment
  • The dissociative effects of ketamine may increase patient vulnerability and the risk of accidents

To promote positive outcomes and ensure safety, follow these ketamine treatment guidelines:

  • Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep
  • Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
  • Continue to take antihypertensive medication as prescribed
  • Do not take ketamine while hungover or with alcoholic beverages
  • Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
  • Ketamine treatment should never be conducted without a peer treatment monitor physically present

A peer-reviewed study of Mindbloom’s client treatment outcomes was published in the Journal of Affective Disorders in 2022, titled At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. The FDA has not evaluated head-to-head trials comparing the safety of ketamine to other medications that are FDA-approved for the treatment of depression, anxiety, or other psychiatric disorders. Although some clients report that they had more success with ketamine than with FDA-approved therapies, these outcomes may not be typical.

For more information about the informed consent that clients review and sign prior to treatment, please visit mindbloom.com/informed-consent.

The Experience

How does a Ketamine therapy session work?

Am I A Candidate?

Preparation

Each new client is sent a Bloombox. The Bloombox is designed to compartmentalize your sessions from other areas of your life. It’s a home base for you to return to when preparing, running, and integrating your medicine sessions.

Intention Setting

Setting intentions before each session is a helpful way to develop goals for your growth. The Mindbloom app includes intention prompts designed by our clinical team to help you clarify what you’re hoping to achieve.

Introspection

Before each session, you’ll take your blood pressure, put on your eye mask, and hold the medicine under your tongue. You’ll start to feel the effects of the dose within 10-15 minutes, and the peak experience will last approximately 30-45 minutes.

Reflection

Each session lasts 1-1.5 hours. Once the session is complete,  you’ll be prompted to recap your experience in your journal. Write down any major themes or insights that were present, as memories of the Ketamine experience can fade quite quickly.

Integration

After taking some time to process the experience , you’ll reunite with your Guide on video. Your guide will help you unpack your experiences, and build a plan to make small changes to your life while your brain is in a fertile state to do so.

Progress

Each program includes 6 treatment sessions. It’s important that each program has a ‘closing.’ a time to reflect on where you were when you started, and where you are today. We offer more advanced programs for clients interested in tackling new goals as they arise.

Am I a Candidate?

Care

Our care team shepherds clients through a safe, impactful experience

Our experienced Clinical and Guide teams spend significant time with clients when compared to traditional psychiatric care. Below are the average touch points for clients in the first two months.

2
Clinician calls
3
Guide consultations
6
Mindbloom sessions
2
Group Sessions
Am I a Candidate?

Preparation

Preparing to embark

Before your first session, you’ll learn what to expect, tips for navigating the experience, and how to set intentions to cultivate a receptive, expansive mindset.

01

Take the assessment

Your journey starts with an online candidate assessment for your indications of depression or anxiety to see if you're a fit.

02

Book your video consult

After signing up, you'll schedule a video consult and psychiatric evaluation with a clinician

03

Set your intentions

You'll be pointing a giant flashlight into your psyche, and where you point it matter! We'll help you direct your inner exploration through intention setting around what you're hoping to overcome and achieve.

Take assessment
New Clients
Returning Clients
$89/week

Billed monthly for three months

Get Started
Insurance reimbursements1
Save with your HSA/FSA2
Risk-free if you’re not a candidate
Included
Ketamine Pill
6 Ketamine Treatments
Bloombox
Bloombox  ($80 Value)
Clinical Consults
2 Clinician Consults
Messaging
3 Guide Sessions + Unlimited Messaging
Group sessions
Unlimited Group Integration Sessions
Add-Ons

1:1 Virtual Integration Coaching
($59 per 45-min session)

Get Started
Insurance reimbursements 1
Save with your HSA/FSA 2
Risk-free if you’re not a candidate
$59/week

Billed monthly for three months

Get Started
Insurance reimbursements1
Save with your HSA/FSA2
Risk-free if you’re not a candidate
Included
Ketamine Pill
6 Ketamine Treatments
Clinical Consults
1 Clinician Consults
Messaging
Unlimited Messaging
Group sessions
Unlimited Group Integration Sessions
Add-Ons

1:1 Virtual Integration Coaching
($59 per 45-min session)

Get Started
Insurance reimbursements 1
Save with your HSA/FSA 2
Risk-free if you’re not a candidate

Here’s What Our
Clients Have to Say

Filter by
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Here’s What Our
Clients Have to Say

During my first session, I was able to dig deep and find the space to forgive myself. It was huge.

Casey W.

I’ve struggled with anxiety, depression, and PTSD for many years. After my first Mindbloom session, I started to feel improvements in my mood and mindset. The cloud of depression has dissipated and my anxiety is now under control.

Kaleb E.

I have tried so many things for my depression and nothing worked. Mindbloom made a noticeable difference in my mood and uncovered the issues that were holding me back from growth.

Ariel H.

Mindbloom introduced me to a stronger version of myself. Someone who isn’t worried, afraid, anxious or depressed. I’m going to be OK.

Carrie C.

For the first time, in a very long time, I woke up happy and excited for a new day.

James K.
Getting off Meds
Appreciation
Safety
Breakthroughs
Trauma
Depression
Grief / Loss
Habits
Anxiety

Read important safety information and view our client outcomes data